Opiranserin

N/A

Report date: 2025/02/27 11:35:35
NME

Base Information

Drug NameOpiranserin
Drug Alias NameopiranserineUnafraVVZ-000149VVZ-149
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsGlycine transporter 2 inhibitorsP2X purinoceptor 3 antagonists
TargetsSerotonin 2a (5-HT2a) receptorGlycine transporter 2P2X purinoceptor 3
Therapy Area/IndicationsAcute PainPain, PostoperativeRadiculopathy +[4] 
Global Approved IndicationsAcute Pain
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2024/12/13
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVivozon Inc
China Registration ClassN/A

Develop Information

Active CompaniesVivozon Pharmaceutical IncBoryungVivozon Inc
Inactive CompaniesThe Brigham and Women's Hospital
Active IndicationsAcute PainPain, Postoperative
Inactive IndicationsRadiculopathySciatica

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank